학술논문

What Plasma Can Tell Us When Tissue Cannot: A Case Report of Genomic Testing in mCRPC and Clinical Response to Treatment With the PARP Inhibitor Rucaparib.
Document Type
Article
Source
Frontiers in Oncology; 8/1/2022, Vol. 12, p1-6, 6p
Subject
PROSTATE cancer
POLY(ADP-ribose) polymerase
CASTRATION-resistant prostate cancer
PROSTATE cancer prognosis
Language
ISSN
2234943X
Abstract
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)